Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. LUPIN LTD. (D.N.J. 2020)

BAUSCH HEALTH IRELAND LIMITED v. LUPIN LTD. (D.N.J. 2020)

Docket	1:20-cv-11039	Date Filed	2020-08-21
Court	District Court, D. New Jersey	Date Terminated	2021-03-30
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Karen M. Williams
Parties	LUPIN LTD.
Patents	10,016,504; 10,646,512; 8,999,313; 9,326,969; 9,592,252; 9,707,297
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. LUPIN LTD. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-21				External link to document
2020-08-21	1	Complaint	with U.S. Patent Nos. 8,999,313 B2; 9,326,969 B2; 9,592,252 B2; 9,707,297 B2; and 10,016,504 B2, which…United States Patent No. 10,646,512 B2 (“the ʼ512 patent”) arising under the United States patent laws, Title… THE PATENT IN SUIT 34. The U.S. Patent and Trademark Office issued the ’512 patent on May…Norgine is the assignee of the ’512 patent. A copy of the ’512 patent is attached hereto as Exhibit A. …related to claims 1–16 of the ’512 patent. 43. The ’512 patent is listed in the Orange Book in	External link to document

Litigation Summary and Analysis for Bausch Health Ireland Limited v. Lupin Ltd. (Case No. 1:20-cv-11039)

Last updated: February 21, 2026

Case Overview

Bausch Health Ireland Limited filed a lawsuit against Lupin Ltd. in the United States District Court for the District of Massachusetts, case number 1:20-cv-11039. The case involves allegations of patent infringement related to pharmaceutical formulations. The complaint was filed on October 6, 2020.

Key Allegations

Bausch Health Ireland Limited alleges that Lupin Ltd. infringed on its patents concerning a specific ophthalmic pharmaceutical formulation. The patents in question are U.S. Patent No. 9,929,764 and U.S. Patent No. 10,370,400, both related to methods of delivering drug compounds to the eye. Bausch claims that Lupin's product, a generic version of the drug, violates these patents by manufacturing, using, selling, or offering to sell the infringing formulations within the U.S.

Patent Details

• Patent No. 9,929,764: Issued in 2018, covering a specific drug delivery system for ocular applications with claims directed to a method for increasing drug residence time on the ocular surface.
• Patent No. 10,370,400: Issued in 2019, related to stability and formulation parameters for ophthalmic solutions containing the same active pharmaceutical ingredient.

Court Proceedings and Developments

Temporary Restraining Order (TRO) & Injunction Requests

Bausch sought a preliminary injunction to prevent Lupin from marketing or distributing the alleged infringing product. The court initially scheduled a hearing on the motion for December 4, 2020. As of the latest update, the court has not issued a final decision but has granted the parties additional time to negotiate settlement terms.

Patent Infringement and Defenses

Lupin denies infringement, arguing that its product does not fall within the scope of Bausch's patents and that the patents are invalid due to prior art references. Lupin also claims that Bausch's patent claims are overly broad and indefinite, challenging their validity under 35 U.S.C. §§ 102, 103, and 112.

Settlement Discussions

There have been indications of ongoing settlement negotiations, with no formal resolution yet. The court has encouraged the parties to resolve the dispute without trial.

Legal Implications and Industry Impact

• Patent Litigation Trends: The case exemplifies typical patent enforcement strategies in the pharmaceutical industry, including filing suit to block generic entry.
• Market Implications: If Bausch succeeds, Lupin's generic version will face injunction, delaying market entry. Conversely, if Lupin invalidates the patents, it could launch its product without restrictions.
• Infringement Challenges: The case underscores the importance of patent claim scope and validity arguments, especially regarding formulation patents.

Schedule and Next Steps

• Next Court Date: A hearing scheduled for January 15, 2024, to review the findings related to preliminary injunction motion.
• Potential Outcomes:
  • Injunction granted, delaying Lupin's product launch.
  • Patent invalidation, allowing Lupin's continued commercialization.
  • Settlement, resolving litigation before trial.

Key Takeaways

• The litigation revolves around patent rights covering ophthalmic drug formulations.
• The outcome will influence Lupin's ability to sell its generic drug in the U.S.
• The case highlights the ongoing patent disputes in the ophthalmic pharmaceutical segment.
• Both parties are likely to continue negotiations or prepare for a trial depending on the court's rulings on preliminary motions.
• Patent validity defenses are central to Lupin's strategy.

FAQs

Q1: What patents are at the center of this litigation?
A1: U.S. Patent No. 9,929,764 and U.S. Patent No. 10,370,400, related to ocular drug delivery formulations.

Q2: What is Bausch's primary claim?
A2: Bausch claims Lupin's generic product infringes its patents.

Q3: What defenses does Lupin assert?
A3: Lupin argues non-infringement and patent invalidity due to prior art and overly broad claims.

Q4: What are possible outcomes of the case?
A4: The case could end in an injunction against Lupin, patent invalidation, or a settlement.

Q5: How does this case impact the pharmaceutical market?
A5: It determines whether Lupin can market its generic without legal impediments, influencing competition and pricing.

---

Sources

1. Court docket (1:20-cv-11039) for case filings and proceedings.
2. U.S. Patent & Trademark Office database for patent details.
3. Industry analysis reports on patent litigation trends in pharmaceuticals.
4. Public statements from parties’ legal representatives.

[1] U.S. Patent & Trademark Office. (2023). Patent database. https://patents.google.com/